Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

Abstract: A method of production of value-added, biobased chemicals, derivative products, and/or purified glycerin from bioglycerin of recycled oil, grease, and/or fat origin is described herein. A method of purification of bioglycerin of recycled oil, grease, and/or fat origin is also described herein. The method of purification of bioglycerin of recycled oil, grease, and/or fat origin described provides methods for desalinating, decolorizing, and/or concentrating bioglycerin of recycled oil, grease, and/or fat origin for the production of biobased chemicals, derivative products, and/or purified glycerin.

Abstract: A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl carbonate group. Using a suitable nucleophile, the pendant pentafluorophenyl carbonate group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

Abstract: A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl carbonate group. Using a suitable nucleophile, the pendant pentafluorophenyl carbonate group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

Abstract: The invention provides compounds of formula I: in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R1-6, a-e and Q are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.

Abstract: Disclosed is an electrolyte comprising a compound having both a sulfonate group and a cyclic carbonate group. The electrolyte forms a more stable and dense SEI layer on the surface of an anode, and thus improves the capacity maintenance characteristics and lifespan characteristics of a battery. Also, disclosed is a compound represented by the following Formula 1, and a method for preparing the same by reacting 4-(hydroxyalkyl)-1,3-dioxolan-2-one with a sulfonyl halide compound: wherein each of R1 and R2 independently represents a C1˜C6 alkylene group optionally containing a C1˜C6 alkyl group or C2˜C6 alkenyl group introduced thereto; R3 is selected from the group consisting of a hydrogen atom, C1˜C20 alkyl group, C3˜C8 cyclic alkyl group, C2˜C6 alkenyl group, halo-substituted alkyl group, phenyl group and benzyl group.

Abstract: An object of the present invention is to provide a nonaqueous electrolytic solution capable of improving low-temperature load characteristics after high temperature charging storage, an electrochemical element using it, and a 1,2-dioxypropane compound used for it. The nonaqueous electrolytic solution of the present invention comprises an electrolyte salt dissolved in a nonaqueous solvent, and contains a 1,2-dioxypropane compound represented by the above-mentioned general formula (I). (wherein R1 and R2 each represent a hydrogen atom, or an alkyl group having from 1 to 6 carbon atoms; X1 represents a group selected from —S(?O)—, —S(?O)2—, —C(?O)—, —CR3R4—, —P(?O)(OR5)— and —SiR6R7—; R3 and R4 each represent a hydrogen atom, or an alkyl group having from 1 to 6 carbon atoms; R5 to R7 each represent an alkyl group having from 1 to 6 carbon atoms.

Abstract: A method of preparing polyurethane prepolymer does not require using a toxic isocyanate monomer (manufactured by harmful phosgene) as a raw material. Epoxy resin and carbon dioxide are used as major raw materials to form cyclic carbonates to be reacted with a functional group oligomer, and then amino groups in a hydrophilic (ether group) or hydrophobic (siloxane group) diamine polymer are used for performing a ring-opening polymerization, and the microwave irradiation is used in the ring-opening polymerization to efficiently synthesize the amino-terminated PU prepolymer, and then an acrylic group at an end is added to manufacture an UV cross-linking PU (UV-PU) oligomer which can be coated onto a fabric surface, and the fabric is dried by UV radiation for a surface treatment to form a washing-resisted long lasting hydrophilic or hydrophobic PU fabric.

Abstract: Disclosed is a method of manufacturing a glycerol carbonate (GC). The method includes a bio-catalyst reaction for generating the GC and byproducts generated by reacting a reactant solution using a lipase of a bio-catalyst. In this instance, the reactant solution is prepared by adding glycerol, a glycerol-containing composition, or a dimethyl carbonate (DMC) in a reaction solvent.

Abstract: This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors.

Abstract: The present invention concerns a compound of following formula (I): where: R1 is H or an alkyl group, A1 is a divalent straight-chain or branched alkylene radical, and A2 is a —O-A4-O— radical, A4 is a divalent straight-chain or branched alkylene radical.

Abstract: A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl carbonate group. Using a suitable nucleophile, the pendant pentafluorophenyl carbonate group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.

Abstract: A process for the manufacture of fluoroethylene carbonate or difluoroethylene carbonate by reaction of ethylene carbonate and F2 or for the manufacture of fluoromethyl methyl carbonate or difluorinated dimethyl carbonate by reaction of dimethyl carbonate and F2 is described wherein such fluorination process is performed continuously.

Abstract: Difluoroethylene carbonate, trifluoroethylene carbonate and tetrafluoroethylene carbonate are synthesized from dichloroethylene carbonate, trichloroethylene carbonate and tetrachloroethylene carbonate with fluorinating agents, e.g. alkali metal fluorides, antimony fluorides and especially the HF adducts of amines The fluorinated carbonates are suitable as additives in lithium ion batteries.

Abstract: This invention is directed to analogs of 5-(tetradecyloxy)-2-furancarboxylic acid (TOFA) and their use in the treatment of dermatological disorders or conditions characterized by sebaceous gland hyperactivity, such as acne and oily skin, and other dermatological disorders and conditions. This invention is also directed to pharmaceutical compositions comprising analogs of TOFA and a pharmaceutically acceptable excipient for dermatological or oral administration.

Abstract: This invention publishes new usages of kinds of carbonic ester compounds. The new usage described in this invention is related to the application of carbonic ester compounds in the preparation of solvents for chemiluminescent systems. This invention also provides luminescent compositions, luminescent liquids and oxidized liquids that contain carbonic ester compounds. Chemiluminescent compositions containing carbonic ester compounds can decrease reaction pressure effectively, facilitate reaction balance heading to luminescence reaction, generate larger luminescent output without adding catalyst, decrease the dosage of catalyst or not need adding catalyst, decrease influences of over-high output at the reaction start caused by catalyst on whole luminescent time, and ensure stable light output from luminescent compositions. Carbonic ester compounds, especially long carbon chain carbonic ester, have the characters of non-toxic and high flash point, and have suitable solubility on ordinary bis oxalate ester.

Abstract: The invention relates to a process for the preparation of fungicidally active compounds such as tricyclic amine derivatives (I). The process involves coupling of a carboxylic 5 acid e.g. a compound of formula (II) with an aniline, e.g. a compound of formula (III) in the presence of a boronic acid catalystor an antimony catalyst (II)(III)(I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y and Het are defined in the specification.

Abstract: The present disclosure is related to a carbon-nanomaterial-supported catalyst, including: a carbon nanomaterial, and a polymer grafted onto the carbon nanomaterial, wherein the polymer has a repeat unit containing a phosphonium salt and its molecular weight is 1,000-200,000. The disclosure is also related to a method of preparing carbonate, which includes using the carbon nanomaterial-supported catalyst for the cycloaddition reaction of carbon dioxide into the epoxy group.

Abstract: Crude fluoroethylene carbonate obtained by the fluorination of ethylene carbonate and elemental fluorine containing not more than 5% by weight of HF is purified by at least two subsequent distillation steps. The bulk of HF can be removed, if desired, in a preliminary HF removal step, e.g., by stripping, before performing the distillation. Further, if desired, a second HF removal step can be performed by contacting the crude mixture or the distillate obtained after the first distillation step with an adsorbent for HF, e.g., silica gel. The distillation can be performed batch wise. It is preferred to perform the distillation continuously. It yields purified fluoroethylene carbonate with an HF content of equal to or less than 30 ppm. The purified fluoroethylene carbonate can be applied as solvent additive for lithium ion batteries.

Abstract: A process for the preparation of 2-oxo-[1,3] dioxolane-4-carboxylic acid esters of formula I with R being an organic group comprising 1 to 10 carbon atoms, wherein an oxirane-2-carboxylic acid ester of formula II is reacted with carbon dioxide (CO2) at a pressure of at least 35 bars and a temperature of 60 to 80° C.

Abstract: A chemical compound of the general formula I or II is useful as feed additive: wherein X=O or NR, and R=H, C1-C6-alkyl (optionally branched), C3-C6-cycloalkyl, aryl, or aralkyl, and wherein R1, R2, are identical or different and in each case H, C1-C6-alkyl (optionally branched), C3-C6-cycloalkyl, allyl, aryl, or aralkyl; or R1 and R2 together are an C2- to C6-alkylene group (optionally C1-C6-alkyl substituted).

Abstract: The present invention concerns 4-fluoro-4-R-5-R?-1,3-dioxolane-2-ones, wherein R is an alkyl group and R? is H or a C1 to C3 alkyl group, their manufacture, solvent mixtures for lithium ion batteries containing them and conductive salt solutions for lithium ion batteries, e.g. solutions containing LiPF6.

Abstract: The invention relates to machine dishwashing agents containing specific polycarbonate-, polyurethane-, and/or polyurea-polyorganosiloxane compounds or precursor compounds thereof of the reactive cyclic carbonate and urea type which help to avoid the formation of water spots and filming after the use of the agents and accelerate the drying of dishes.

Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

Abstract: Dimeric aluminium catalysts of formula I: and their use in catalysing the synthesis of cyclic carbonates from epoxides and carbon dioxide.

Abstract: 2-Oxo-1,3-dioxolane-4-carboxylic acid and derivatives thereof, according to the following formula, in which R1 represents a negative charge, hydrogen or may be methyl or ethyl or an n-valent radical, which may be substituted with at most n?1 further 2-oxo-1,3-dioxolane-4-carboxyl groups, as well as a process for their preparation by means of carboxylation of the corresponding epoxides, a process for their transesterification and their use for the preparation of hydroxyurethanes and as end groups for the blocking of amines.

Abstract: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.

Abstract: A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl carbonate group. Using a suitable nucleophile, the pendant pentafluorophenyl carbonate group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.

Abstract: Novel fluorinated cyclic carbonate compounds are described. These compounds may be useful as non-aqueous electrolyte solvents, specialty solvents, and starting materials and intermediates for synthesis of dyes, agricultural chemicals, and pharmaceuticals.

Abstract: The present invention relates to a synthesis process of polyol carbonate, such as glycerol carbonate, from polyols such as glycerol, propylene glycol or ethylene glycol and urea conducted in using a solvent selective for polyols (glycerol) carbonates. Said process comprises reacting polyol with urea in the presence of a catalyst, extracting produced NH3 and in addition in the presence in the course of at least one step of the process of a selective solvent for polyol carbonate allowing to extract it from the reaction medium.

Abstract: Processes for preparing monochloroethylene carbonate include reacting ethylene carbonate with chlorine gas in a liquid phase under irradiation of UV light and introducing a separate feed of an inert gas into the liquid phase. Monochloroethylene carbonate may be subsequently converted to vinylene carbonate.

Abstract: Process for the preparation of cyclic carbonates by reacting a polyhydric alcohol with a dialkyl carbonate in the presence of a heterogeneous catalyst, wherein the heterogeneous catalyst is a basic mixed oxide or a basic oxide applied to a support.

Abstract: There is provided a process for preparing a fluoropropylene carbonate safely at high yield by one step (one pot), and the process is characterized by allowing a fluorinating agent to act on a propylene carbonate derivative having a group to be released in a fluorination reaction.

Abstract: A cyclic carbonate monomer, including: wherein R1, R2, and R3 are independently selected from the group consisting of H, linear or branched, substituted or unsubstituted alkyl; R10 is a connecting group selected from the group consisting of linear or branched, substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; R4 is an optional bridging group selected from the group consisting of linear or branched, substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, heterocyclic, aryl and heteroaryl; Z is selected from the group consisting of O, NH, NR, and S; G is a guanidine group; and P is a protecting group. The cylic carbonate monomer can be reacted with an initiator including a drug, drug candidate, probe or other molecule of interest to form an oligomer with the molecule of interest attached to one end of a carbonate backbone and guanidine groups attached to the carbonate backbone.

Abstract: The present invention relates to solid forms of 13-(N-Boc-?-isobutylserinyl)-14-?-hydroxybaccatin III 1,14-carbonate (Ortataxel). Amorphous Form A, crystalline Form B, mixtures thereof and processes for preparing them are disclosed. Amorphous Form A is prepared by fast precipitation of Ortataxel from a mixture of acetone and water. Form A transforms in Form B when suspended and stirred in a mixture of ethanol and water for 4-8 hours. If the suspension is stirred for less than 4 hours, mixtures of Form B and Form A are obtained. Form B or mixtures of Forms A and B can also be obtained dissolving Ortataxel in a protic organic solvent, followed by addition of water.

Abstract: The present invention relates to a process for producing glycidol from glycerol carbonate as a raw material with a high yield. The process for producing glycidol according to the present invention includes the steps of (1) reducing a content of a salt having a weak acidity in glycerol carbonate to 1500 ppm by mass or less; and (2) obtaining the glycidol from the glycerol carbonate.

Abstract: The invention provides compounds of Formula (I), pharmaceutical compositions and methods of synthesis thereof.

Abstract: A dimeric aluminium(salen) catalyst of formula I: wherein: Y-Q is CRC1?N or CRC1RC2—NRN1, where RC1, RC2 and RN1 are independently selected from H, halo, optionally substituted C1-20 alkyl, optionally substituted C5-20 aryl, ether and nitro; each of the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16, is independently selected from H, halo, optionally substituted C1-20 alkyl, optionally substituted C5-20 aryl, optionally substituted C3-20 heterocyclyl, ether and nitro; X1 and X2 are independently either (i) a C2-5 alkylene chain, which is optionally substituted by one or more groups selected from C1-4 alkyl and C5-7 aryl, or a C1-3 bisoxyalkylene chain, which is optionally substituted by one or more groups selected from C1-4 alkyl and C5-7 aryl or (ii) represent a divalent group selected from C5-7 arylene, C5-7 cyclic alkylene and C3-7 heterocyclylene, which may be optionally substituted; (i) (a) at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13,

Abstract: The present invention provides a process for preparing fluorinated 1,3-dioxolan-2-one by reacting a derivative of 1,3-dioxolan-2-one having halogen atom other than fluorine with an amine hydrofluoride in an organic solvent, and in this preparation process, fluorinated 1,3-dioxolane-2-on can be prepared in a short period of time by liquid-liquid reaction while maintaining high yield, by using a derivative of 1,3-dioxolan-2-one having halogen atom other than fluorine as a starting material and fluorinating the derivative with a fluorinating agent.

Abstract: The present invention relates to a process for producing glycidol from glycerol carbonate by subjecting the glycerol carbonate to decarboxylation reaction in the presence of a solvent containing no active hydrogen. In the process, glycidol can be produced from glycerol carbonate as a raw material of the glycidol with a high selectivity.

Abstract: The present invention relates to cosmetic compositions and more particularly to skin-whitening cosmetic compositions comprising senkyunolide A as an active ingredient. The present invention discloses the novel inhibitory function of senkyunolide A isolated from Cnidium officinale and Ligusticum chuanxiong on the melanocyte-stimulating hormone (MSH), and provides MSH-inhibitory compositions and skin-whitening cosmetic compositions comprising the senkyunolide A. The compositions of the present invention show significantly enhanced skin-whitening effect owing to its efficient inhibition of MSH even in lower concentration.

Abstract: The present invention provides a compound of formula I?; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention relates to novel dispersants containing at least two lipophilic groups, and the dispersants contain a hydrophilic component present in an amount sufficient to at least partially disperse the amphiphilic compound in aqueous media. The invention further provides for the use of the novel dispersants in various applications.

Abstract: The present invention relates to a process for preparing highly pure glyceryl carbonate by transesterifying dialkyl carbonates or cyclic carbonates in the presence of a basic catalyst.

Abstract: Compositions of matter comprising 5-phenylalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or veterinary patients, including autoimmune diseases such as multiple sclerosis. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds may be due at least in part to potassium channel inhibition.

Abstract: One aspect of the present invention relates to a method for the kinetic resolution of racemic and diastereomeric mixtures of chiral compounds. The critical elements of the method are: a non-racemic chiral tertiary-amine-containing catalyst; a racemic or diastereomeric mixture of a chiral substrate, e.g., a cyclic carbonate or cyclic carbamate; and a nucleophile, e.g., an alcohol, amine or thiol. A preferred embodiment of the present invention relates to a method for achieving the kinetic resolution of racemic and diastereomeric mixtures of derivatives of ?- and ?-amino, hydroxy, and thio carboxylic acids. In certain embodiments, the methods of the present invention achieve dynamic kinetic resolution of a racemic or diastereomeric mixture of a substrate, i.e.

Abstract: This disclosure is directed to an integrated method for making synthetic hydrocarbon fluids, plasticizers and polar synthetic lubricant base stocks from a renewable feedstock. More particularly, the disclosure is directed to a metathesis reaction of natural oil or its derivative ester and ethylene in the presence of an effective amount of a metathesis catalyst to form linear alpha-olefins, internal olefins and reduced chain length triglycerides. The linear alpha-olefins and/or internal olefins are polymerized to produce synthetic hydrocarbon fluids in the presence of a suitable catalyst. The reduced chain length triglycerides are converted into polar synthetic lubricant base stocks or plasticizers by hydrogenation, isomerization, followed by hydrogenations, or by hydroisomerization processes. Alternatively, the reduced chain length triglycerides can also be epoxidized to form epoxidized triglyceride plasticizers, optionally followed by carbonation, to form carbonated triglyceride plasticizers.

Abstract: A crystalline, completely soluble lithium bis(oxalato)borate (LiBOB), to a method for producing the same and to the use of the lithium bis(oxalato)borate.